Welcome to our dedicated page for United Therapeutics news (Ticker: UTHR), a resource for investors and traders seeking the latest updates and insights on United Therapeutics stock.
United Therapeutics Corporation (UTHR) is a pioneering biotechnology company dedicated to developing and commercializing innovative products that address unmet medical needs for patients with chronic and life-threatening conditions. The company's core business revolves around the creation of treatments for pulmonary arterial hypertension (PAH), a rare and progressive disease characterized by high blood pressure in the lungs' arteries. United Therapeutics' therapies predominantly focus on the prostacyclin pathway, with many treatments based on the molecule treprostinil.
With five approved products on the market, United Therapeutics is relentless in its mission to deliver 'medicines for life.' The company's long-term vision includes providing an unlimited supply of transplantable organs to those in need. Employees collaborate across the United States, Europe, and Asia to achieve this ambitious goal.
In addition to its focus on PAH, the company is also dedicated to researching and developing treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases. United Therapeutics markets a pediatric oncology drug, but its primary focus remains on advancing therapeutics for PAH.
United Therapeutics has seen significant achievements in recent years, continually pushing the boundaries of medical science. Their financial condition remains robust, driven largely by sales within the United States. The company is actively engaged in various partnerships and projects aimed at enhancing their therapeutic offerings and expanding their global footprint.
United Therapeutics Corporation (Nasdaq: UTHR) will report its fourth quarter and full year 2021 financial results on February 24, 2022, before market opening. A public webcast will take place at 9:00 a.m. ET on the same day. The company emphasizes its commitment to developing therapies for pulmonary arterial hypertension and expanding organ availability. As a public benefit corporation, it aims to balance patient and shareholder interests while promoting sustainability.
Forward-looking statements include anticipated clinical developments, subject to risks and uncertainties.
United Therapeutics (Nasdaq: UTHR) announced significant advancements in xenotransplantation with the world's first genetically-modified heart transplant (UHeart™) reaching a two-week milestone, showcasing normal organ function. Additionally, the UKidney™ procedure's data was published in the American Journal of Transplantation, marking a first in peer-reviewed studies. The UThymoKidney™ was noted for its historic preclinical study, furthering the quest for sustainable organ supply. These innovations reinforce United Therapeutics' commitment to transforming organ transplantation and improving patient outcomes.
United Therapeutics Corporation (Nasdaq: UTHR) announced that Martine Rothblatt, Ph.D., and Michael Benkowitz will engage in a fireside chat hosted by J.P. Morgan's biotech analyst, Jessica Fye. This virtual event is scheduled for January 6, 2022, from 8:00 a.m. to 8:45 a.m. EST, featuring updates on the company’s mission and business. Access will be through a live webcast, with an archived version available after the session. The company continues to pioneer treatments for pulmonary arterial hypertension and aims to expand organ transplant availability.
United Therapeutics announced a 17% increase in total revenue for Q3 2021, reaching $444.7 million compared to $380.1 million in Q3 2020. Net income fell 5% to $162.7 million, with non-GAAP earnings rising 14% to $198 million. The company highlighted a growing patient base for its Tyvaso therapy, now with approximately 4,000 patients in the USA. Additionally, progress in six phase 3 clinical trials was noted, indicating a robust pipeline for pulmonary hypertension treatments.
United Therapeutics Corporation (Nasdaq: UTHR) will present an update on its business at the Credit Suisse 30th Annual Healthcare Conference on November 8, 2021, from 8:50 a.m. to 9:30 a.m. EST. Michael Benkowitz, President and COO, will lead the discussion. The session will be available via live webcast on the company's website, with an archived version accessible 24 hours post-event for 90 days. United Therapeutics aims to cure pulmonary arterial hypertension and is notable for being the first publicly-traded company structured as a public benefit corporation.
Volumetric, a Houston-based biofabrication start-up, has been acquired by 3D Systems (NYSE: DDD) for an initial payment of
United Therapeutics Corporation (Nasdaq: UTHR) has announced it will release its third quarter 2021 financial results on November 3, 2021, before the market opens. A public webcast will take place on the same day at 9:00 a.m. Eastern Time, accessible via the company's website. The company focuses on finding a cure for pulmonary arterial hypertension and has received FDA approval for five medications. United Therapeutics operates as a public benefit corporation, aiming to enhance shareholder value while promoting sustainability and healthcare advancements.
On October 21, 2021, United Therapeutics (Nasdaq: UTHR) presented significant clinical data at CHEST 2021 regarding pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The highlight was the new pharmacokinetic data from the BREEZE study of Tyvaso DPI, which showed comparable systemic exposure to existing Tyvaso treatments with reduced variability. The data indicate successful transitions from Tyvaso to Tyvaso DPI, enhancing patient outcomes, such as improved walking distance and overall satisfaction.
United Therapeutics Corporation (Nasdaq: UTHR) announced a setback in the FDA review of its new drug application for Tyvaso DPI™ for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). On October 15, 2021, the FDA issued a complete response letter citing a single deficiency at a third-party testing facility, delaying approval. The company aims to resolve this issue and anticipates resubmission by summer 2022.
FAQ
What is the current stock price of United Therapeutics (UTHR)?
What is the market cap of United Therapeutics (UTHR)?
What does United Therapeutics Corporation specialize in?
How many approved products does United Therapeutics have?
What is pulmonary arterial hypertension?
What is the company's long-term mission?
Where are United Therapeutics' employees located?
What molecule forms the basis of many of the company's treatments?
Does United Therapeutics market any oncology drugs?
What drives United Therapeutics' financial condition?
Is United Therapeutics involved in partnerships?
What are the latest news and developments from United Therapeutics?
